Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 83,857 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Not applicable Interventional Results available

Multi-Site Evaluation of Progressive Tinnitus Management

NCT01015781
View directory record Official record
Conditions
Tinnitus
Interventions
Progressive Tinnitus Management, Wait List Control
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
West Haven, Connecticut • Portland, Oregon • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CBT for Anxiety in Children With Autism

NCT02725619
View directory record Official record
Conditions
Autism Spectrum Disorder, Anxiety
Interventions
CBT, PST
Behavioral
Lead sponsor
Yale University
Other
Eligibility
8 Years to 14 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

NCT02128919
View directory record Official record
Conditions
Schizophrenia, Cognition, Cigarette Smoking
Interventions
tDCS
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions

NCT07345130
View directory record Official record
Conditions
Bioequivalence, Bioavailability
Interventions
Advil Tablet (Mini) (Test Product), Advil Tablet (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Phase 2 Interventional

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

NCT06806930
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Carcinoma, Breast
Interventions
Neoadjuvant endocrine therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

NCT02171130
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Interventions
Nasal Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy

NCT03083379
View directory record Official record
Conditions
Ventilation, Breathing, Atelectasis
Interventions
Volumetric Incentive Spirometry, EzPAP® POSITIVE AIRWAY PRESSURE
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

NCT02283762
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

NCT07020988
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato Alprazolam, Midazolam, Diazepam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
20 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

NCT00753688
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
PAZOPANIB, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
Biological · Procedure
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

NCT00445003
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
Drug · Behavioral · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
56
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 23, 2026, 6:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

NCT01708161
View directory record Official record
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions
BYL719, AMG 479
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

NCT00231842
View directory record Official record
Conditions
Uterine Cancer
Interventions
Ifosfamide, Radiation Therapy, Cisplatin
Drug · Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Muscle Fatigue and Kinesio Taping on Shoulder Position Sense

NCT02104570
View directory record Official record
Conditions
Fatigue, Proprioception
Interventions
Kinesio taping with tension, Kinesio taping without tension, Fatigue protocol
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 23, 2026, 6:21 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

NCT07811869
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Tampa, Florida • Brighton, Massachusetts • Clarkston, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Black Tea Intake on Serum Lipids

NCT01882283
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Tea Treatment Group, Placebo
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT04253483
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Ablative Radiotherapy
Radiation · Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 23, 2026, 6:21 PM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT01897441
View directory record Official record
Conditions
Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy
Drug · Other · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction

NCT01018394
View directory record Official record
Conditions
Tobacco Dependence
Interventions
nicotine lozenges, tobacco-free snuff
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 6:21 PM EDT